Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders
Jamie Leckie, Sunny Wu, Terryanne Standell, Toshifumi Yokota · 2025
Read Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders by Jamie Leckie, Sunny Wu, Terryanne Standell, Toshifumi Yokota (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12732681.txt.
Description
Jamie Leckie and co-authors review smart software for designing gene-silencing drugs for rare muscle diseases in a 2025 paper. These drugs, short strands that bind gene messages, can skip faulty parts or break bad messages down. Approved versions often work weakly, in part due to poor strand design.
New platforms use machine learning to pick strand order and chemistry for each target. Early tools show real promise, yet proof is thin and safety checks are rarely built in. The authors say sharper, well-tested design could cut lab screening and speed cures. Less expert teams could also craft strong candidates with such aid.
Catalog record
| CREATOR | Jamie Leckie, Sunny Wu, Terryanne Standell, Toshifumi Yokota |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |